ondansetron has been researched along with Pulmonary Disease, Chronic Obstructive in 1 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Pulmonary Disease, Chronic Obstructive: A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objectives of this study were to determine the effect of single and repeat dosing with oral ondansetron, a 5-HT3-specific receptor blocker, on the degree and duration of bronchodilation induced by inhaled ipratropium bromide in patients with COPD." | 2.73 | Bronchodilating effect of combined therapy with ipratropium bromide and ondansetron in patients with COPD. ( Faiferman, I; Fogarty, C; Hirschberg, S; Joos, GF; Pauwels, R; Vessey, R; Wouters, EF, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pauwels, R | 1 |
| Joos, GF | 1 |
| Fogarty, C | 1 |
| Faiferman, I | 1 |
| Hirschberg, S | 1 |
| Vessey, R | 1 |
| Wouters, EF | 1 |
1 trial available for ondansetron and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Bronchodilating effect of combined therapy with ipratropium bromide and ondansetron in patients with COPD.
Topics: Administration, Inhalation; Administration, Oral; Adult; Aged; Bronchodilator Agents; Cross-Over Stu | 2008 |